0
No votes yet
Article

Taxanes as a First-Line Systemic Treatment in Metastatic Breast Cancer

Laura M. Urquhart
CJON 2013, 17(1), 15-21 DOI: 10.1188/13.CJON.S1.15-21

First-line treatment of metastatic breast cancer (MBC) is an important therapeutic setting. Effective treatment of MBC in the initial setting can extend a patient's life and provide significant improvements in quality of life. The taxanes paclitaxel, docetaxel, and nab-paclitaxel have been investigated as first-line therapy for MBC requiring chemotherapy in numerous trials. Results from these trials have demonstrated that taxanes are effective treatments in MBC but also have highlighted differences in their toxicity profiles. Those differences must be taken into consideration when deciding the appropriate treatment for each patient. This article explores the differences among the agents in efficacy and safety in the first-line setting for treating MBC. In addition, administration concerns unique to each taxane are discussed.

References 

Bishop, J.F., Dewar, J., Toner, G.C., Smith, J., Tattersall, M.H.N., Olver, I.N., … Taxol Investigational Trials Group, Australia/New Zealand. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. <i>Journal of Clinical Oncology, 17</i>, 2355-2364.

Blum, J.L., Dees, E.C., Chacko, A., Doane, L., Ethriajan, S., Hopkins, J., … O'Shaughnessy, J.A. (2006). Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. <i>Journal of Clinical Oncology, 24</i>, 4384-4390. doi:10.1200/JCO.2005.05.1383

Bristol-Myers Squibb. (2011). <i>Taxol® (paclitaxel)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://packageinserts.bms.com/pi/pi_taxol.pdf'>http://packageinserts.bms...

Celgene Corporation. (2012). <i>Abraxane® (nab-paclitaxel)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://www.abraxane.com/hcp/download/Abraxane_Prescribing_Information.pd...

Conlin, A.K., Seidman, A.D., Bach, A., Lake, D., Dickler, M., D'Andrea, G., … Hudis, C.A. (2010). Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. <i>Clinical Breast Cancer, 10</i>, 281-287. doi:10.3816/CBC.2010.n.036

Cortes, J., & Saura, C. (2010). Nanoparticle albumin-bound (nab)-paclitaxel: Improving efficacy and tolerability by targeted drug delivery in MBC. <i>European Journal of Cancer Supplements, 8</i>, 10. doi:10.1016/S1359-6349(10)70002-1

Crawford, J., Dale, D.C., & Lyman, G.H. (2004). Chemotherapy-induced neutropenia. <i>Cancer, 100</i>, 228-237. doi:10.1002/cncr.11882

Gennari, A., Conte, P., Rosso, R., Orlandini, C., & Bruzzi, P. (2005). Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. <i>Cancer, 104</i>, 1742-1750.

Ghersi, D., Wilcken, N., & Simes, R.J. (2005). A systematic review of taxane-containing regimens for metastatic breast cancer. <i>British Journal of Cancer, 93</i>, 293-301. doi:10.1038/sj.bjc.66 02680

Gonzalez, I.D., Saez, R.S, Rodilla, E.F., Yges, E.L., & Toledano, F.L. (2000). Hypersensitivity reactions to chemotherapy drugs. <i>Journal of Allergy and Clinical Immunology, 15</i>, 161-181.

Gradishar, W.J., Krasnojon, D., Cheporov, S., Makhson, A.N., Manikhas, G.M., Clawson, A., & Bhar, P. (2009). Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. <i>Journal of Clinical Oncology, 27</i>, 3611-3619. doi:10.1200/JCO.2008.18.5397

Gradishar, W.J., Krasnojon, D., Cheporov, S.V., Makhson, A.N., Manikhas, G.M., Clawson, A., & Iglesias, J. (2012). Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Final analysis of overall survival. <i>Clinical Breast Cancer, 12</i>, 313-321. doi:10.1016/j.clbc.2012.05.001

Gradishar, W.J., Meza, L.A., Amin, B., Samid, D., Hill, T., Chen, Y.M., … Marcom, P.K. (2004). Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. <i>Journal of Clinical Oncology, 22</i>, 2321-2327. doi:10.1200/JCO.2004.12.128

Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., … O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. <i>Journal of Clinical Oncology, 23</i>, 7794-7803. doi:10.1200/JCO.2005.04.937

Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. <i>Journal of the National Cancer Institute, 91</i>, 1616-1634.

Jones, S.E., Erban, J., Overmoyer, B., Budd, G.T., Hutchins, L., Lower, E., & Ravdin, P.M. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. <i>Journal of Clinical Oncology, 23</i>, 5542-5551. doi:10.1200/JCO.2005.02.027

Kingston, D.G. (2007). The shape of things to come: Structural and synthetic studies of Taxol and related compounds. <i>Phytochemistry, 68</i>, 1844-1854. doi:10.1016/j.phytochem.2006.11.009

Lema, M.J., Foley, K.M., & Hausheer, F.H. (2010). Types and epidemiology of cancer-related neuropathic pain: The intersection of cancer pain and neuropathic pain. <i>Oncologist, 15</i>(Suppl. 2), 3-8. doi:10.1634/theoncologist.2009-S505

Lobo, C., Lopes, G., Baez, O., Castrellon, A., Ferrell, A., Higgins, C., … Glück, S. (2010). Final results of a phase II study of <i>nab</i>-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment, 123</i>, 427-435. doi:10.1007/s10549-010-1002-0

Miles, D.W., Chan, A., Dirix, L.Y., Cortes, J., Pivot, X., Tomczak, P., … Romieu, G. (2010). Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor-2 negative metastatic breast cancer. <i>Journal of Clinical Oncology, 28</i>, 3239-3247. doi:10.1200/JCO.2008.21.6457

Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., … Davidson, N.E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. <i>New England Journal of Medicine, 357</i>, 2666-2676. doi:10.1056/NEJMoa072113

Mirtsching, B., Cosgriff, T., Harker, G., Keaton, M., Chidiac, T., & Min, M. (2011). A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. <i>Clinical Breast Cancer, 11</i>, 121-128. doi:10.3816/CBC.2011.n.011

Nabholtz, J.M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., … TAX 306 Study Group. (1993). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. <i>Journal of Clinical Oncology, 21</i>, 968-975.

Nabholtz, J.M., Gelmon, K., Bontenbal, M., Spielmann, M., Gatimel, G., Conte, P., … Winograd, B. (1996). Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. <i>Journal of Clinical Oncology, 14</i>, 1858-1867.

Nabholtz, J.M., Senn, H.J., Bezwoda, W.R., Melnychuk, D., Deschenes, L., Douma, J., … Aapro, M. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. <i>Journal of Clinical Oncology, 17</i>, 1413-1424.

National Cancer Institute. (2012). Breast cancer treatment PDQ. Retrieved from <a target="_blank" href='http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofession...

National Comprehensive Cancer Network. (2012). <i>NCCN Clinical Practice Guidelines in Oncology: Breast cancer</i> [v.3.2012]. Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf'>http://w...

Paridaens, R., Biganzoli, L., Bruning, P., Klign, J.G.M., Gamucci, T., Houston, S., … European Organisation for Research and Treatment of Cancer—Investigational Drug Branch for Breast Cancer/Early Clinical Studies Group. (2000). Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organisation for Research and Treatment of Cancer randomized study with cross-over. <i>Journal of Clinical Oncology, 18</i>, 724-733.

Ropka, M.E., & Padilla, G. (2007). Assessment of neutropenia-related quality of life in a clinical setting. <i>Oncology Nursing Forum, 34</i>, 403-409. doi:10.1188/07.ONF.403-409

Roy, V., LaPlant, B.R., Gross, G.G., Bane, C.L., Palmieri, F.M., & North Central Cancer Treatment Group. (2009). Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (NO531). <i>Annals of Oncology, 20</i>, 449-453. doi:10.1093/annonc/mdn661

Rugo, H.S., Barry, W.T., Moreno-Aspitia, A., Lyss, A.P., Cirrincione, C., Mayer, E.L., … Winer, E.P. (2012, June). <i>CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer</i> [Presentation CRA1002]. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.

sanofi-aventis. (2010). <i>Taxotere® (docetaxel)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://products.sanofi.us/Taxotere/taxotere.html'>http://products.sanofi...

Schwartzberg, L.S., Arena, F.P., Mintzer, D.M., Epperson, A.L., & Walker, M.S. (2012). Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. <i>Clinical Breast Cancer, 12</i>, 87-93. doi:10.1016/j.clbc.2011.10.004

Seidman, A.D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P.K., … Hudis, C. (2008). Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non-overexpressors: Final results of Cancer and Leukemia Group B Protocol 9840. <i>Journal of Clinical Oncology, 26</i>, 1642-1649. doi:10.1200/JCO.2007.11.6699

Sledge, G.W., Neuberg, D., Bernardo, P., Ingle, J.N., Martino, S., Rowinsky, E.K., & Wood, W.C. (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). <i>Journal of Clinical Oncology, 21</i>, 588-592.

Sparreboom, A., Baker, S.D., & Verweij, J. (2005). Paclitaxel repackaged in albumin-stabilized nanoparticle: Handy or just a dandy? <i>Journal of Clinical Oncology, 23</i>, 7765-7767. doi:10.1200/JCO.2005.03.7135

Stemmler, H.J., Harbeck, N., Gröll de Rivera, I., Vehling Kaiser, U., Rauthe, G., Abenhardt, W., … Heinemann, V. (2010). Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer. <i>Oncology, 79</i>, 197-203. doi:10.1159/000320640

Syrigou, E., Dannos, I., Kotteas, E., Makrilla, N., Tourkantonis, I., Dilana, K., … Syrigos, K.N. (2011). Hypersensitivity reactions to docetaxel: Retrospective evaluation and development of a desensitization protocol. <i>International Archives of Allergy and Immunology, 156</i>, 320-324. doi:10.1159/000324454

U.S. Food and Drug Administration. (2011). Commissioner statement: FDA commissioner removes breast cancer indication from Avastin label. Retrieved from <a target="_blank" href='http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm'...

U.S. Food and Drug Administration. (2012). Drugs@FDA: Taxotere. Retrieved from <a target="_blank" href='http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseacti...

Valachis, A., Polyzos, N.P., Patsopoulos, N.A., Georgoulias, V., Mavroudis, D., & Marui, D. (2010). Bevacizumab in metastatic breast cancer: A meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment, 122</i>, 1-7. doi:10.1007/s10549-009-0727-0

Weiss, R.B., Donehower, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., … Leyland-Jones, B. (1990). Hypersensitivity reactions from Taxol. <i>Journal of Clinical Oncology, 8</i>, 1263-1268.